European Headache Alliance

Monthly Archives: October 2018

Master of Headache Disorder

Copenhagen University is now offering a Master on Headache Disorders. It´s a continuing professional development programme for healthcare professionals. The programme requires a minimum of 6 individual visits to Copenhagen, Denmark over a two-year period: Modules 1 to 4 are organized with an e-learning self-study period followed by one week of face-to-face sessions at University of…
Read More

Migraine Association of Ireland

Migraine Awareness Week 2018 MAI held an accredited Health Care Professional Seminar, during which two international speakers presented on Migraine: Diagnosis and Treatment, and the Development of the new Anti-CGRP medication. Prof. Lars Edvinsson and Prof. Allan Purdy, both members of the IHS, followed this up by doing a webinar for members of the Irish…
Read More

How to access innovative treatments by FindMeCure Foundation

FindMeCure Widget  Medical science has been rapidly advancing in the recent decades and we can prove that with many examples: new therapies for diabetes, the first vaccine for the prevention of cervical cancer, oral treatments for Hepatitis C curing more than 90% of the cases, the first Lupus drug in 50 years, personalized medicines to…
Read More

#MoveForMigraine

#MoveForMigraine Migraine remains an overlooked and misunderstood condition in many parts of Europe, including Belgium. The disease suffers from a lack of recognition and understanding, even from the first concerned parties (patients, caregivers, employers, etc.). This comes at a significant burden for the patients and at a high cost for society (1,650,000 working days lost…
Read More

Lilly Receives Positive CHMP Opinion for Emgality

INDIANAPOLIS, Sept. 21, 2018 Lilly Receives Positive CHMP Opinion for EmgalityTM (galcanezumab) for the Prophylaxis of Migraine in Adults Eli Lilly and Company announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Emgality TM (galcanezumab) for the prophylaxis of migraine in adults who have at least…
Read More

European Civic Prize on Chronic Pain

Active Citizenship Network launch the second edition of the bi-annual research-project at the European level “EU Civic Prize on Chronic Pain - Collection of good practices” with the aim to continue to give evidence on existing good practices in several European countries in terms of the struggle against pain. Aims of the project Giving continuity…
Read More

Patient Solidarity Day 2018

On Friday 7 December 2018, patient advocates and stakeholders from all world regions will stand together, united in a celebration of Patient Solidarity Day (PSD). This year’s theme is about ‘Safe Medication and Healthcare for All’ and it aims to raise awareness on these critical global public health issues and advocate for access to safe, quality and appropriate medicines…
Read More

Lilly’s Emgality Approved

INDIANAPOLIS, Sept. 27, 2018 Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA) has approved Emgality™ (galcanezumab-gnlm) 120 mg injection for the preventive treatment of migraine in adults. Emgality offers a once-monthly, self-administered, subcutaneous injection. Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients. Emgality will be available…
Read More

EMHA New Corporate Website

European Migraine and Headache Alliance (EMHA) has launched a new version of its corporate website: www.emhalliance.org The website has a number of new features to improve user experience, including: A complete refreshed homepage where we have implemented a calendar in which users can see the great activity of EMHA for every month, all the congresses,…
Read More